Data as reported by national authorities by 10 AM CET 13 March 2020
Coronavirus disease 2019 (COVID-19)
Situation Report – 53
SITUATION IN NUMBERS
total and new cases in last 24
hours
Globally
132 758 confirmed (7499 new)
4955 deaths (342 new)
China
80 991 confirmed (11 new)
3180 deaths (07 new)
Outside of China
51 767 confirmed (7488 new)
1775 deaths (335 new)
122 countries/territories/
areas (5 new)
WHO RISK ASSESSMENT
China
Regional Level
Global Level
HIGHLIGHTS
• Five new countries/territories/areas (Jersey, Réunion, Saint Vincent and the
Grenadines, Cuba and Guyana) have reported cases of COVID-19 in the past
24 hours.
• The WHO, UN Foundation and partners launched a first-of-its-kind COVID-19
Solidarity Response Fund today. The fund will raise money from a wide range
of donors to support the work of the WHO and partners to help countries
respond to the COVID-19 pandemic. For more details, please see here.
• Since the onset of the COVID-19 outbreak, Infection Prevention and Control
(IPC) has been a major factor in preventive and mitigation measures. To ensure
evidence-based quality guidance and prompt response to global demand,
WHO convened a WHO Health Emergencies Programme Experts Advisory
Panel for IPC. For more information, please see ‘subject in focus’.
• A team of experts from WHO, Global Outbreak Alert and Response Network
partners, the Robert Koch Institute in Germany and the Chinese Center for
Disease Control concluded a technical support mission on COVID-19 to Iran on
10 March 2020. During the team’s mission in Iran, the Ministry of Health and
Medical Education (MOHME) launched a national campaign to control COVID-
19. For more information on the mission, please see here.
Figure 1. Countries, territories or areas with reported confirmed cases of COVID-19, 13 March 2020
SUBJECT IN FOCUS: Infection Prevention and Control (IPC) – update
Since the onset of the COVID-19 outbreak, IPC has played a major role in preventive and mitigation measures. To
ensure evidence-based quality guidance and prompt response to global demand, WHO convened a WHO Health
Emergencies (WHE) Programme Ad-Hoc Experts Advisory Panel for Infection Prevention and Control, which is attended
by members of the Global Infection Prevention and Control Network (GIPCN), members of relevant institutions, and
Member States affected by COVID-19. This advisory panel supports the WHE IPC pillar with timely advice on
preparedness, readiness and response to COVID-19 based on evidence where available. They hold weekly discussions
on the technical aspects of IPC measures, and shared experiences across affected countries. The following
guidance/tools have been issued, in consultation with this global IPC advisory panel:
1. Health workers exposure risk assessment and management in the context of COVID-19 virus. This tool is to
be used by health care facilities that have either cared for or admitted COVID-19 patients; it is to be
completed for all health care workers (HCW) who have been exposed to a confirmed COVID-19 patient in a
health care facility. It helps determine the risk of COVID-19 virus infection of the HCW who have been
exposed to a COVID-19 patient and provides recommendations for appropriate management of these HCWs,
according to their infection risk.
2. Considerations for quarantine of individuals in the context of containment for coronavirus disease (COVID-
19) The purpose of this document is to offer guidance to Member States on quarantine measures for
individuals in the context of COVID-19. It is intended for those responsible for establishing local or national
policy for quarantine of individuals, and adherence to infection prevention and control measures in these
settings.
3. In collaboration with WASH colleagues including UNICEF, the team has developed a briefing on water,
sanitation, hygiene and waste management for COVID-19. More information can be found here.
WHO IPC specialists are currently supporting a number of countries and have been deployed to support the response
in cooperation with IPC teams in Italy and Iraq, amongst other countries.
The online course “Infection Prevention and Control (IPC) for COVID-19” has been translated into Russian and
Japanese. As of 13 March, 38 725 people have registered for the course. Infographics, including videos (e.g. when and
how to use a mask), are being developed on demand,
To support the preparedness, readiness and response for COVID-19, WHO has convened teleconferences in
cooperation with other partners, including with Africa CDC/CDC/ECHO and with the World Organization of Family
Doctors – Africa, to develop and contribute IPC information.
SURVEILLANCE
Table 1. Confirmed and suspected cases of COVID-19 acute respiratory disease reported by provinces, regions and
cities in China, Data as of 13 March 2020
Province/
Region/
City
Population
(10,000s)
In last 24 hours
Cumulative
Confirmed
cases
Suspected
cases
Deaths
Confirmed
cases
Deaths
Hubei
5917
5
1
6
67786
3062
Guangdong
11346
0
0
0
1356
8
Henan
9605
0
0
0
1273
22
Zhejiang
5737
0
0
0
1215
1
Hunan
6899
0
0
0
1018
4
Anhui
6324
0
0
0
990
6
Jiangxi
4648
0
0
0
935
1
Shandong
10047
0
0
1
760
7
Jiangsu
8051
0
0
0
631
0
Chongqing
3102
0
0
0
576
6
Sichuan
8341
0
0
0
539
3
Heilongjiang
3773
0
0
0
482
13
Beijing
2154
1
9
0
436
8
Shanghai
2424
2
23
0
346
3
Hebei
7556
0
0
0
318
6
Fujian
3941
0
0
0
296
1
Guangxi
4926
0
0
0
252
2
Shaanxi
3864
0
0
0
245
2
Yunnan
4830
0
0
0
174
2
Hainan
934
0
0
0
168
6
Guizhou
3600
0
0
0
146
2
Tianjin
1560
0
0
0
136
3
Shanxi
3718
0
0
0
133
0
Hong Kong SAR
745
2
0
0
131
3
Gansu
2637
0
0
0
127
2
Liaoning
4359
0
0
0
125
1
Jilin
2704
0
0
0
93
1
Xinjiang
2487
0
0
0
76
3
Ningxia
688
0
0
0
75
0
Inner Mongolia
2534
0
0
0
75
1
Taipei and environs
2359
1
0
0
49
1
Qinghai
603
0
0
0
18
0
Macao SAR
66
0
0
0
10
0
Xizang
344
0
0
0
1
0
Total
142823
11
33
7
80991
3180
Table 2. Countries, territories or areas outside China with reported laboratory-confirmed COVID-19 cases and
deaths. Data as of 13 March 2020
*
Reporting Country/
Territory/Area
†
Total
confirmed
‡
cases
Total
confirmed
new cases
Total
deaths
Total
new
deaths
Transmission
classification
§
Days since last
reported case
Western Pacific Region
Republic of Korea
7979
110
66
0
Local transmission
0
Japan
675
55
19
4
Local transmission
0
Singapore
187
9
0
0
Local transmission
0
Australia
140
18
3
0
Local transmission
0
Malaysia
129
0
0
0
Local transmission
2
Philippines
52
0
2
0
Local transmission
1
Viet Nam
39
0
0
0
Local transmission
1
Brunei Darussalam
12
0
0
0
Imported cases only
1
Cambodia
5
2
0
0
Local transmission
0
New Zealand
5
0
0
0
Local transmission
6
Mongolia
1
0
0
0
Imported cases only
3
Territories
**
French Polynesia
1
0
0
0
Imported cases only
1
European Region
Italy
15113
2651
1016
189
Local transmission
0
Spain
2965
825
84
36
Local transmission
0
France
2860
591
61
13
Local transmission
0
Germany
2369
802
6
3
Local transmission
0
Switzerland
858
213
6
2
Local transmission
0
Denmark
674
59
0
0
Local transmission
0
Sweden
620
159
0
0
Local transmission
0
Netherlands
614
111
5
0
Local transmission
0
The United Kingdom
594
134
8
2
Local transmission
0
Austria
361
59
1
1
Local transmission
0
Belgium
314
0
0
0
Local transmission
1
Norway
489
0
0
0
Local transmission
1
Czechia
116
22
0
0
Local transmission
0
Finland
109
69
0
0
Local transmission
0
Greece
98
0
1
0
Local transmission
1
Israel
75
0
0
0
Local transmission
2
Ireland
70
27
1
0
Local transmission
0
San Marino
63
0
2
0
Local transmission
2
Iceland
61
0
0
0
Local transmission
3
Slovenia
57
0
0
0
Local transmission
1
Poland
49
5
1
1
Local transmission
0
Romania
48
0
0
0
Local transmission
1
Portugal
41
0
0
0
Local transmission
2
Russian Federation
34
14
0
0
Imported cases only
0
Georgia
25
2
0
0
Imported cases only
0
Albania
23
13
0
0
Imported cases only
0
Slovakia
21
11
0
0
Local transmission
0
Serbia
19
0
0
0
Under investigation
1
Luxembourg
17
0
0
0
Imported cases only
1
Croatia
16
0
0
0
Local transmission
2
Hungary
16
3
0
0
Local transmission
0
Latvia
16
0
0
0
Imported cases only
1
Estonia
13
0
0
0
Imported cases only
2
Belarus
12
0
0
0
Local transmission
1
Azerbaijan
11
2
0
0
Imported cases only
0
Malta
9
3
0
0
Imported cases only
0
Bulgaria
7
0
1
0
Local transmission
1
North Macedonia
7
0
0
0
Local transmission
3
Cyprus
6
0
0
0
Imported cases only
1
Bosnia and
Herzegovina
4
0
0
0
Local transmission
2
Liechtenstein
4
3
0
0
Imported cases only
0
Republic of Moldova
4
0
0
0
Imported cases only
1
Lithuania
3
0
0
0
Imported cases only
1
Ukraine
3
2
0
0
Imported cases only
0
Andorra
1
0
0
0
Imported cases only
10
Armenia
1
0
0
0
Imported cases only
11
Holy See
1
0
0
0
Under investigation
7
Monaco
1
0
0
0
Under investigation
12
Turkey
1
0
0
0
Imported cases only
1
Territories
**
Faroe Islands
2
0
0
0
Imported cases only
4
Gibraltar
1
0
0
0
Under investigation
9
Guernsey
1
0
0
0
Imported cases only
3
Jersey
2
2
0
0
Imported cases only
0
South-East Asia Region
Thailand
75
5
1
0
Local transmission
0
India
74
1
1
1
Local transmission
0
Indonesia
34
0
1
0
Local transmission
1
Maldives
8
0
0
0
Local transmission
2
Bangladesh
3
0
0
0
Local transmission
4
Sri Lanka
3
1
0
0
Imported cases only
0
Bhutan
1
0
0
0
Imported cases only
7
Nepal
1
0
0
0
Imported cases only
49
Territories
**
Réunion
3
3
0
0
Imported cases only
0
Eastern Mediterranean Region
Iran (Islamic Republic
of)
10075
1075
429
75
Local transmission
0
Qatar
262
0
0
0
Imported cases only
1
Bahrain
195
6
0
0
Local transmission
0
United Arab Emirates
85
11
0
0
Local transmission
0
Kuwait
80
0
0
0
Imported cases only
1
Iraq
70
0
7
0
Local transmission
1
Egypt
67
0
1
0
Local transmission
1
Lebanon
66
0
3
0
Local transmission
1
Saudi Arabia
21
0
0
0
Imported cases only
1
Pakistan
20
1
0
0
Local transmission
0
Oman
18
0
0
0
Imported cases only
3
Afghanistan
7
0
0
0
Imported cases only
1
Tunisia
7
1
0
0
Imported cases only
0
Morocco
6
1
1
0
Imported cases only
0
Jordan
1
0
0
0
Imported cases only
10
Territories
**
occupied Palestinian
territory
31
1
0
0
Local transmission
0
Region of the Americas
United States of
America
1264
277
36
7
Local transmission
0
Canada
138
45
1
0
Local transmission
0
Brazil
77
25
0
0
Local transmission
0
Chile
33
10
0
0
Local transmission
0
Argentina
31
12
1
0
Imported cases only
0
Costa Rica
22
9
0
0
Local transmission
0
Peru
22
5
0
0
Local transmission
0
Ecuador
17
0
0
0
Local transmission
1
Panama
14
4
1
0
Imported cases only
0
Mexico
12
1
0
0
Imported cases only
0
Colombia
9
0
0
0
Imported cases only
1
Dominican Republic
5
0
0
0
Imported cases only
3
Paraguay
5
0
0
0
Imported cases only
2
Bolivia (Plurinational
State of)
3
1
0
0
Imported cases only
0
Cuba
3
3
0
0
Imported cases only
0
Honduras
2
0
0
0
Imported cases only
1
Guyana
1
1
1
1
Imported cases only
0
Jamaica
1
0
0
0
Imported cases only
2
Saint Vincent and the
Grenadines
1
1
0
0
Imported cases only
0
Territories
**
French Guiana
6
1
0
0
Imported cases only
0
Martinique
4
1
0
0
Imported cases only
0
Saint Martin
2
0
0
0
Under investigation
10
Saint Barthelemy
1
0
0
0
Under investigation
10
African Region
Algeria
25
0
1
0
Local transmission
1
South Africa
17
4
0
0
Imported cases only
0
Senegal
10
6
0
0
Imported cases only
0
Burkina Faso
2
0
0
0
Imported cases only
2
Cameroon
2
0
0
0
Local transmission
6
Nigeria
2
0
0
0
Imported cases only
4
Cote d Ivoire
1
0
0
0
Imported cases only
1
Democratic Republic
of the Congo
1
0
0
0
Imported cases only
2
Togo
1
0
0
0
Imported cases only
6
Subtotal for all
regions
51071
7488
1768
335
International
conveyance
(Diamond Princess)
696
0
7
0
Local transmission
5
Grand total
51767
7488
1775
335
*
Numbers include both domestic and repatriated cases
†
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on
the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its
frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
‡
Case classifications are based on WHO case definitions for COVID-19.
§
Transmission classification is based on WHO analysis of available official data and may be subject to reclassification as additional data become
available. Countries/territories/areas experiencing multiple types of transmission are classified in the highest category for which there is
evidence; they may be removed from a given category if interruption of transmission can be demonstrated. It should be noted that even within
categories, different countries/territories/areas may have differing degrees of transmission as indicated by the differing numbers of cases and
other factors. Not all locations within a given country/territory/area are equally affected.
Terms:
- Community transmission is evidenced by the inability to relate confirmed cases through chains of transmission for a large number of cases, or by
increasing positive tests through sentinel samples (routine systematic testing of respiratory samples from established laboratories).
- Local transmission indicates locations where the source of infection is within the reporting location.
- Imported cases only indicates locations where all cases have been acquired outside the location of reporting.
- Under investigation indicates locations where type of transmission has not been determined for any cases.
- Interrupted transmission indicates locations where interruption of transmission has been demonstrated (details to be determined)
** “Territories” include territories, areas, overseas dependencies and other jurisdictions of similar status
Figure 2. Epidemic curve of confirmed COVID-19 cases reported outside of China, by date of report and WHO
region through 13 March 2020
PREPAREDNESS AND RESPONSE
• To view all technical guidance documents regarding COVID-19, please go to this webpage.
• WHO has developed interim guidance for laboratory diagnosis, advice on the use of masks during home care and
in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak, clinical management,
infection prevention and control in health care settings, home care for patients with suspected novel
coronavirus, risk communication and community engagement and Global Surveillance for human infection with
novel coronavirus (2019-nCoV).
• WHO is working closely with International Air Transport Association (IATA) and have jointly developed a
guidance document to provide advice to cabin crew and airport workers, based on country queries. The
guidance can be found on the IATA webpage.
• WHO has been in regular and direct contact with Member States where cases have been reported. WHO is also
informing other countries about the situation and providing support as requested.
• WHO is working with its networks of researchers and other experts to coordinate global work on surveillance,
epidemiology, mathematical modelling, diagnostics and virology, clinical care and treatment, infection
prevention and control, and risk communication. WHO has issued interim guidance for countries, which are
updated regularly.
• WHO has prepared a disease commodity package that includes an essential list of biomedical equipment,
medicines and supplies necessary to care for patients with 2019-nCoV.
• WHO has provided recommendations to reduce risk of transmission from animals to humans.
• WHO has published an updated advice for international traffic in relation to the outbreak of the novel
coronavirus 2019-nCoV.
• WHO has activated the R&D blueprint to accelerate diagnostics, vaccines, and therapeutics.
• OpenWHO is an interactive, web-based, knowledge-transfer platform offering online courses to improve the
response to health emergencies. COVID-19 courses can be found here. Specifically, WHO has developed online
courses on the following topics: A general introduction to emerging respiratory viruses, including novel
coronaviruses (available in Arabic, English, French, Chinese, Spanish, Portuguese, and Russian); Critical Care of
Severe Acute Respiratory Infections (available in English and French); Health and safety briefing for respiratory
STRATEGIC OBJECTIVES
WHO’s strategic objectives for this response are to:
• Interrupt human-to-human transmission including reducing secondary infections among close contacts
and health care workers, preventing transmission amplification events, and preventing further
international spread*;
• Identify, isolate and care for patients early, including providing optimized care for infected patients;
• Identify and reduce transmission from the animal source;
• Address crucial unknowns regarding clinical severity, extent of transmission and infection, treatment
options, and accelerate the development of diagnostics, therapeutics and vaccines;
• Communicate critical risk and event information to all communities and counter misinformation;
• Minimize social and economic impact through multisectoral partnerships.
*This can be achieved through a combination of public health measures, such as rapid identification, diagnosis
and management of the cases, identification and follow up of the contacts, infection prevention and control in
health care settings, implementation of health measures for travelers, awareness-raising in the population and
risk communication.
diseases - ePROTECT (available in English, French, and Russian); Infection Prevention and Control for Novel
Coronavirus (COVID-19) (available in English and Russian); and COVID-19 Operational Planning Guidelines and
COVID-19 Partners Platform to support country preparedness and response.
• WHO is providing guidance on early investigations, which are critical in an outbreak of a new virus. The data
collected from the protocols can be used to refine recommendations for surveillance and case definitions, to
characterize the key epidemiological transmission features of COVID-19, help understand spread, severity,
spectrum of disease, impact on the community and to inform operational models for implementation of
countermeasures such as case isolation, contact tracing and isolation. Several protocols are available here. One
such protocol is for the investigation of early COVID-19 cases and contacts (the “First Few X (FFX) Cases and
contact investigation protocol for 2019-novel coronavirus (2019-nCoV) infection”). The protocol is designed to
gain an early understanding of the key clinical, epidemiological and virological characteristics of the first cases of
COVID-19 infection detected in any individual country, to inform the development and updating of public health
guidance to manage cases and reduce the potential spread and impact of infection.
RECOMMENDATIONS AND ADVICE FOR THE PUBLIC
If you are not in an area where COVID-19 is spreading or have not travelled from an area where COVID-19 is
spreading or have not been in contact with an infected patient, your risk of infection is low. It is understandable that
you may feel anxious about the outbreak. Get the facts from reliable sources to help you accurately determine your
risks so that you can take reasonable precautions (see Frequently Asked Questions). Seek guidance from WHO, your
healthcare provider, your national public health authority or your employer for accurate information on COVID-19
and whether COVID-19 is circulating where you live. It is important to be informed of the situation and take
appropriate measures to protect yourself and your family (see Protection measures for everyone).
If you are in an area where there are cases of COVID-19 you need to take the risk of infection seriously. Follow the
advice of WHO and guidance issued by national and local health authorities. For most people, COVID-19 infection
will cause mild illness however, it can make some people very ill and, in some people, it can be fatal. Older people,
and those with pre-existing medical conditions (such as cardiovascular disease, chronic respiratory disease or
diabetes) are at risk for severe disease (See Protection measures for persons who are in or have recently visited (past
14 days) areas where COVID-19 is spreading).
CASE DEFINITIONS
WHO periodically updates the Global Surveillance for human infection with coronavirus disease (COVID-19)
document which includes case definitions.
For easy reference, case definitions are included below.
Suspect case
A. A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease (e.g.,
cough, shortness of breath), AND with no other etiology that fully explains the clinical presentation AND a
history of travel to or residence in a country/area or territory reporting local transmission (See situation
report) of COVID-19 disease during the 14 days prior to symptom onset.
OR
B. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-
19 case (see definition of contact) in the last 14 days prior to onset of symptoms;
OR
C. A patient with severe acute respiratory infection (fever and at least one sign/symptom of respiratory disease
(e.g., cough, shortness breath) AND requiring hospitalization AND with no other etiology that fully explains
the clinical presentation.
Probable case
A suspect case for whom testing for COVID-19 is inconclusive.
• Inconclusive being the result of the test reported by the laboratory
Confirmed case
A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.
• Information regarding laboratory guidance can be found here.